Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Francesca Bruce

Francesca Bruce has been writing news and analysis about all things affecting the pharmaceutical industry since 2008. She has paid special attention to policy and regulatory developments but particularly likes to write about market access and how medicines may  - or may not  -  make it to patients. She generally writes about Europe, but really enjoys uncovering news from further corners of the globe, especially Latin America and the Middle East.
Advertisement
Set Alert for Articles By Francesca Bruce

Latest From Francesca Bruce

Canada Introduces World's First 48-Hour Reporting Requirement

New regulations in Canada could mean companies are required to notify the country's regulator more quickly about foreign-risk communications and conduct new post-marketing safety tests.

Canada Regulation

Canada Introduces World First 48-Hour Reporting Requirement

New regulations in Canada could mean companies are required to notify the regulator more quickly about foreign risk communications and conduct new post-marketing safety tests.

Drug Safety BioPharmaceutical

Oncology Combo Drugs Face UK Market Access Disappointment

New oncology drugs forming new treatment combinations will face a tough ride through England’s influential health technology appraisal body, NICE.

BioPharmaceutical Policy

Canada Considers Performance-Based Outcome Reimbursement Deals For Oncology Drugs

Manufacturers selling oncology drugs in Canada could soon face group price negotiations and performance-based reimbursement agreements as authorities in the country plan to improve access to oncology drugs.

Market Access Canada

Brazil Prepares To Make Its Own Sovaldi As Regulator Opposes Patent Application

Brazil could soon be manufacturing its own generic version of Gilead’s Sovaldi if opposition to the company’s patent application is upheld by the patent office.

Intellectual Property Market Access

Tendering: The New Hot Topic In Pharma

Pharmaceutical companies with maturing portfolios need to understand tendering if they want to prevent international price erosion.

Market Access Business Strategies
See All
Advertisement
UsernamePublicRestriction

Register